Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEKTAR THERAPEUTICS Director's Dealing 2017

Feb 6, 2017

32134_dirs_2017-02-06_b7f896e5-b366-462b-a662-d1a6d7551351.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-02-02

Reporting Person: Nicholson John (SVP & Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-02-02 Common Stock M 66495 $4.65 Acquired 206821 Direct
2017-02-02 Common Stock S 66495 $12.38 Disposed 140326 Direct
2017-02-03 Common Stock M 8505 $4.65 Acquired 148831 Direct
2017-02-03 Common Stock S 8505 $12.48 Disposed 140326 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-02-02 Employee Stock Option (right to buy) $4.65 M 66495 Disposed 2017-02-22 Common Stock (66495) Direct
2017-02-03 Employee Stock Option (right to buy) $4.65 M 8505 Disposed 2017-02-22 Common Stock (8505) Direct

Footnotes

F1: The Reporting Person exercised and sold a portion of the Shares of common stock subject to this stock option that expires on February 22, 2017, with the objective of using substantially all of the proceeds to cover the exercise price of the entire stock option and applicable withholding taxes.

F2: This price reflects the weighted average sale price for open-market sales of Shares made by the Reporting Person on February 2, 2017. The actual prices for these transactions range from $12.20 to $12.45, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

F3: This price reflects the weighted average sale price for open-market sales of Shares made by the Reporting Person on February 3, 2017. The actual prices for these transactions range from $12.45 to $12.51, inclusive.

F4: This stock option became fully vested on February 23, 2013 and will expire on February 22, 2017 if not exercised.